Press Releases BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.3959 ^USD	-1.02%		+4.21%	-40.39%

01/05	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI
30/04	Transcript : BioCardia, Inc. - Special Call

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	09/05	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	01/05	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04	AQ
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03	AQ
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03	AQ
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03	AQ
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02	AQ
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	31/01	AQ
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	03/01	AQ
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12	AQ
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12	AQ
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K	18/12	PU
BioCardia : Material Event - Form 8-K	06/12	PU
BioCardia : Shareholder Meeting - Form 8-K	06/12	PU
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval	29/11	AQ
BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K	17/11	PU
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules	16/11	AQ
BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure	14/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioCardia, Inc.

Equities

BCDA

US09060U5074

Press Releases

Filters